Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
AMTEC IIT: Phase 2 Multiarm Study in TNBC
NCT03801369 · Gordon Mills, MD, PhD · PHASE2 · terminated · last registry update 2026-02-25 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “loss of funding” | Open Targets' class: business administrative | Registry record, Gordon Mills, MD, PhD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, LY2780301 + paclitaxel (NCT01980277)
- 2026-02-02Results posted on the registry: AstraZeneca, Durvalumab + Capivasertib (NCT03742102)
- 2026-01-28Results posted on the registry: Canadian Cancer Trials Group, Ipatasertib + Fulvestrant (NCT04650581)
- 2025-12-24Also stopped (withdrawn): Imperial College London, Capivasertib (NCT06613516)
- 2025-12-15Phase 3 first posted: Women's Cancer Study Group GmbH, Capivasertib (NCT07281833)
- 2025-12-01Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Atezolizumab Injection + Bevacizumab (NCT05180006)
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody + Bevacizumab (NCT03280563)
- 2025-10-27Results posted on the registry: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2025-05-28Results posted on the registry: Rutgers, The State University of New Jersey, a drug against AKT2 (NCT03326713)
- 2025-05-21Phase 3 first posted: Relay Therapeutics, Inc., Zovegalisib + Capivasertib (NCT06982521)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision